A 40something woman was thought to be too young for glaucoma but more people below age 60 are being diagnosed with glaucoma ...

Genomics can help to identify people who are more likely to develop glaucoma potentially long before any symptoms of the disease appear. Instead ...

Physiologic AL varies materially with age, sex, height, and ethnicity, undermining fixed AL thresholds as broadly applicable risk stratifiers in typical pediatric myopia. Retinal pathology risk ...

Health experts in Plateau and Kaduna States have raised an alarm over the growing burden of glaucoma, urging Nigerians to undergo ...

Medical experts in Plateau State have raised serious concerns over the rate at which glaucoma is spreading in the state, with over 4,000 cases recorded in ...

Glaucoma develops when fluid inside the eye doesn’t drain properly, causing pressure to build up over time and damage the optic nerve ...

Qlaris Bio appointed Fred Guerard, PharmD, as its president and CEO, according to a press release. The company is entering phase 3 development of QLS-111, a novel eye drop for lowering IOP in patients ...

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...

SpyGlass Pharma Inc., which is promising an intraocular lens that will reshape the treatment of glaucoma, emerged from its initial public offering last month with a big boost from Wall Street.

The US Food and Drug Administration (FDA) has granted permission to conduct the first clinical trials of cell rejuvenation therapy in humans. This was reported by the journal Nature Biotechnology.

Open-angle glaucoma is a risk factor for vascular and frontotemporal dementia in patients with type 2 diabetes, according to a study.

DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.